Previous 10 | Next 10 |
Gainers: Itamar (NASDAQ:ITMR) +46%. Aterian (NASDAQ:ATER) +40%. aTyr Pharma (NASDAQ:LIFE) +37%. iRhythm Technology (NASDAQ:IRTC) +34%. BELLUS (NASDAQ:BLU) +26%. Leap Therapeutics (NASDAQ:LPTX) +30%. REGENXBIO (NASDAQ:RGNX) +25%. Datasea (NASDAQ:DTSS) +20%. Uranium Royalty (NASDAQ:UROY) ...
Shares of MiMedx Group (NASDAQ: MDXG) are down more than 60% as of 12:15 p.m. EDT today after a pair of clinical trials failed to demonstrate their intended benefits. The biotech focuses on regenerative medicine using amniotic tissue as a platform. The results today were fro...
Gainers: Itamar Medical ITMR +45%, aTyr Pharma LIFE +35%, iRhythm Technologies (NASDAQ:IRTC) +33%, REGENXBIO RGNX +20%, Leap Therapeutics LPTX +15%. Losers: MiMedx MDXG -61%, Silverback Therapeutics (NASDAQ:SBTX) -24%, Dynavax T...
Phase 2B Knee Osteoarthritis (KOA) Study Top-line Interim Results Demonstrate Varied Efficacy Signals between Patient Cohorts Company to Pursue Phase 3 KOA Confirmatory Studies Initial Review of Phase 3 Plantar Fasciitis Trial Data Does Not Support a Biologics License Ap...
MARIETTA, Ga., Sept. 08, 2021 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, today announced the shelf registration statement on Form S-3 ...
MARIETTA, Ga., Sept. 07, 2021 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, today announced that Timothy R. Wright, Chief Executive Offic...
My portfolio, built specifically for my retirement ~20+ years from now, eclipses new highs as the market continues to grind higher. Making monthly contributions, even though they seem small at the time, makes all the difference in the world over time in helping create a valuable retir...
S-3 Eligibility Enabled by Accomplishment of Multiple Financial Milestones MARIETTA, Ga., Aug. 27, 2021 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), an industry leader in utilizing amniotic tissue as a platform for ...
New study shows advanced treatment (AT) for management of LEDUs among Medicare beneficiaries is associated with significant reductions in major and minor amputation, emergency department (ED) use, and hospital readmissions vs. LEDUs managed without AT (NAT) MARIETTA, Ga., Aug. 17,...
Promotion Recognizes Skilled Leadership and Contributions to MIMEDX’s Continued Growth MARIETTA, Ga., Aug. 12, 2021 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), an industry leader in utilizing amniotic tissue as a ...
News, Short Squeeze, Breakout and More Instantly...
Study adds to the Company’s growing body of evidence and expands the understanding of the regulatory capabilities of its DHACM and LHACM allografts on the fibrotic process Marks MIMEDX’s first publication in the 5 th most-cited journal in the world MARIET...
Rick Barry appointed Executive Chairman of the Board Remi Barbier resigns as President and CEO and from the Board of Directors Cassava initiates search for a new CEO AUSTIN, Texas, July 17, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) today announced that the Boa...
MARIETTA, Ga., July 17, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the second quarter ended June 30, 2024 after the market close on Wednesday, July 3...